Dimension Therapeutics, Inc
DMTX
DMTX was delisted on the 6th of November, 2017.
35 hedge funds and large institutions have $25.7M invested in Dimension Therapeutics, Inc in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 16 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $32.7M → $25.7M (-$6.96M)
26% less funds holding
Funds holding: 47 → 35 (-12)
56% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 16
75% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$115K |
| 2 |
Renaissance Technologies
New York
|
+$84.8K |
| 3 |
ECM
Element Capital Management
New York
|
+$84.6K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
+$74.8K |
| 5 |
Goldman Sachs
New York
|
+$73.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$674K |
| 2 |
State Street
Boston,
Massachusetts
|
-$231K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$213K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$141K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$108K |
DMTX Hedge Fund Activity: Q2 2017 in Review
35 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Dimension Therapeutics, Inc (DMTX) for Q2 2017, worth a combined $25.7M — down 21% from $32.7M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of DMTX and 4 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 7 added.
The largest buyer was Millennium Management, adding an estimated $115K. The largest seller was BlackRock, cutting an estimated $674K.
- 35 institutional investors held Dimension Therapeutics, Inc (DMTX) as of Q2 2017, down from 47 in Q1 2017.
- Funds reported $25.7M of Dimension Therapeutics, Inc stock for Q2 2017, down 21% quarter-over-quarter.
- 4 funds opened new Dimension Therapeutics, Inc positions in Q2 2017 and 16 closed out, a net change of -12 holders.
- The largest Dimension Therapeutics, Inc buyer in Q2 2017 was Millennium Management, an estimated $115K added.
- The largest Dimension Therapeutics, Inc seller in Q2 2017 was BlackRock, an estimated $674K sold.
Based on aggregated 13F filings for Q2 2017.